Last reviewed · How we verify
Ethinyl estradiol / dienogest
Ethinyl estradiol and dienogest work together as a combined oral contraceptive, suppressing ovulation through hormonal feedback on the hypothalamic-pituitary-ovarian axis.
Ethinyl estradiol and dienogest work together as a combined oral contraceptive, suppressing ovulation through hormonal feedback on the hypothalamic-pituitary-ovarian axis. Used for Contraception, Treatment of endometriosis-associated pain.
At a glance
| Generic name | Ethinyl estradiol / dienogest |
|---|---|
| Also known as | Valette, ATC code G03AA |
| Sponsor | Helsinki University Central Hospital |
| Drug class | Combined oral contraceptive |
| Target | Estrogen receptor, progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Gynecology |
| Phase | FDA-approved |
Mechanism of action
Ethinyl estradiol is a synthetic estrogen that inhibits follicle-stimulating hormone (FSH) secretion, while dienogest is a progestin that suppresses luteinizing hormone (LH) and increases cervical mucus viscosity. Together, they prevent ovulation and create an unfavorable environment for sperm transport and implantation, providing contraceptive efficacy.
Approved indications
- Contraception
- Treatment of endometriosis-associated pain
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
- "Quick-starting" of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition (NA)
- The Progression From Dysmenorrhoea to Chronic Pelvic Pain
- Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery (PHASE3)
- To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada) (PHASE3)
- Role of Medical Treatment in Endometriosis Patients Undergoing ICSI (NA)
- Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis Patients (NA)
- The Use of Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation (PHASE4)
- The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ethinyl estradiol / dienogest CI brief — competitive landscape report
- Ethinyl estradiol / dienogest updates RSS · CI watch RSS
- Helsinki University Central Hospital portfolio CI